Daniel Rayson
Overview
Explore the profile of Daniel Rayson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1123
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loggie J, Barnes P, Carter M, Rayson D, Bethune G
Breast
. 2024 Mar;
75:103715.
PMID: 38520994
Purpose: It remains unclear whether patients with HER2-negative, low-estrogen receptor (ER-low)-positive early breast cancer (BC) benefit from Oncotype DX® (ODX) testing. Methods: We conducted a retrospective review of cases referred...
2.
Henning J, Brezden-Masley C, Gelmon K, Chia S, Shapera S, McInnis M, et al.
Curr Oncol
. 2023 Sep;
30(9):8019-8038.
PMID: 37754497
Ongoing advances in precision cancer therapy have increased the number of molecularly targeted and immuno-oncology agents for a variety of cancers, many of which have been associated with a risk...
3.
Rayson D, Gandhi S, Joy A, Brezden-Masley C, Gelmon K, Sehdev S, et al.
Curr Oncol
. 2023 May;
30(5):5050-5053.
PMID: 37232839
We appreciate the opportunity to respond to the comment [...].
4.
Sheridan M, Colwell B, Lamond N, Macfarlane R, Rayson D, Snow S, et al.
Curr Oncol
. 2023 Mar;
30(3):3149-3159.
PMID: 36975451
(1) Background: Cancer is the leading cause of death in Canada, with significant resource limitation impacting the delivery of cancer care nationwide. The onset of the COVID-19 pandemic forced additional...
5.
Rayson D, Gandhi S, Joy A, Brezden-Masley C, Gelmon K, Sehdev S, et al.
Curr Oncol
. 2022 Dec;
29(12):9891-9895.
PMID: 36547192
The addition of pertuzumab to neoadjuvant trastuzumab and chemotherapy for women with early-stage, high-risk, HER2+ breast cancer has been observed to lead to higher pathologic complete response rates (pCR), and...
6.
Liwski C, Castonguay M, Barnes P, Rayson D, Bethune G
Ann Diagn Pathol
. 2022 Apr;
59:151953.
PMID: 35487077
Current guidelines recommend HER2 testing on all primary invasive breast cancers and re-biopsy at disease relapse. The discordance rate between HER2-negative primaries and HER2 IHC2+ metastases that are ISH-amplified is...
7.
8.
Simmons C, Rayson D, Joy A, Henning J, Lemieux J, McArthur H, et al.
Ther Adv Med Oncol
. 2022 Jan;
14:17588359211066677.
PMID: 35035535
Background: Evidence to date supports continued human epidermal growth factor receptor 2 (HER2) suppression beyond progression on HER2-directed therapy for advanced HER2-positive breast cancer. Data from several phase II and...
9.
DeCoste R, Carter M, Barnes P, Andea A, Wang M, Rayson D, et al.
J Cutan Pathol
. 2021 Jun;
48(11):1397-1403.
PMID: 34152024
Cutaneous apocrine carcinomas share common features with their counterparts in the breast; hence, metastatic mammary carcinoma must be excluded before such lesions can be designated primary cutaneous neoplasms. Primary tumors...
10.